Adcytherix Launches and Raises 30 Million Euros in Seed Funding to Develop New Generation Antibody Conjugates

11 June 2024

Adcytherix SAS announced today its creation and the closing of a seed round of 30 million euros to develop new antibody conjugates (ADC) to treat pathologies in strong medical need, particularly cancer.

The company was founded by Jack Elands and Pontifax Venture Capital, and counts Xavier Preville and Carsten Dehning as co-founders. The Adcytherix management team consists of Jack Elands (CEO), Carsten Dehning (CFO) and Xavier Preville (VP, head of research and preclinical development).

The first funding round was led by Pontifax and supported by Pureos Bioventures, RA Capital Management and Dawn Biopharma (a platform controlled by KKR). The management team also participated in this seed round.

Jack Elands, CEO of Adcytherix, comments: “Our new company aims to address the most pressing needs of patients by developing a new generation of ADCs. We are delighted that the leading investors and partners who have supported us accompanied by Emergence have joined us again to support us in achieving our objectives".

Ran Nussbaum, Partner at Pontifax Venture Capital added: “We are delighted to participate in this new adventure with an excellent management team who have already worked with us. ADCs will play a major role in the future of oncology. The team that runs the company and the union that will support Adcytherix aim to build a highly differentiated franchise in this space.”

As part of the seed funding, Ran Nussbaum and Ohad Hammer of Pontifax, Ximing Ding of Pureos Bioventures, Iyona Rajkomar of Dawn Biopharma and Matthew Hammond of RA Capital Management joined the Adcytherix Oversight Committee.

For more information, please contact:


Jack Elands, Chief Executive Officer M: +33 6 38 35 70 08

About Adcytherix

Adcytherix is ​​a biopharmaceutical company focused on developing novel antibody-drug conjugates (ADCs) to treat diseases with unmet need, such as cancer. The company is led by an experienced management team and draws on a network of world-renowned experts in the field of ADC development.

Adcytherix is ​​backed by a syndicate of leading life sciences investors, including Pontifax, Pureos Bioventures, RA Capital Management and Dawn Biopharma (a platform controlled by KKR). Adcytherix is ​​based in Marseille, France. For more information, please visit .